Larger trials needed for Parkinson's disease

Most trials of drug treatment for Parkinson's disease have crucial methodological faults and provide little reliable evidence on differences between classes of drugs, argue Wheatley and colleagues (p 1508). They believe that much larger trials are needed with long term follow up and end points of relevance to patients, and suggest that those who treat patients with Parkinson's disease must accept the need for large pragmatic trials and participate in them.
 
(Credit: SIMON FRASER/SPL)



Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Evaluating drug treatments for Parkinson's disease: how good are the trials?
Keith Wheatley, Rebecca L Stowe, Carl E Clarke, Robert K Hills, Adrian C Williams, and Richard Gray
BMJ 2002 324: 1508-1511. [Extract] [Full Text] [PDF]

Access jobs at BMJ Careers
Whats new online at Student BMJ